FrancophonIA/ELRC3.0 huggingface dataset:
English: The primary target organs identified in the repeat-dose toxicology studies by parenteral routes (intravenous or subcutaneous) up to 1-year duration in mice and monkeys were the lymphoid and haematopoietic system.
Estonian: Hiirtel ja ahvidel läbi viidud korduvtoksilisuse uuringutes (ravimit manustati parenteraalselt - intravenoosselt või subkutaanselt - kuni 1 aasta jooksul)
English: Women of childbearing potential must prevent pregnancy by use of effective contraception during cladribine treatment and for at least 6 months after the last dose (see section 4.5).
Estonian: Fertiilses eas naised peavad kladribiinravi ajal ja vähemalt 6 kuud pärast viimase annuse võtmist vältima rasestumist efektiivsete rasestumisvastaste vahendite abil (vt lõik 4.5).
English: No studies have been conducted in patients with hepatic impairment.
Estonian: Maksafunktsiooni kahjustusega patsientidel ei ole uuringuid läbi viidud.
English: Distribution of dose
Estonian: Annuse jaotamine
English: An infection commonly seen with MAVENCLAD is shingles.
Estonian: MAVENCLAD'i kasutamisel sageli esinev nakkus on vöötohatis.
English: MAVENCLAD contains sorbitol
Estonian: MAVENCLAD sisaldab sorbitooli
English: No dedicated studies have been conducted in patients with renal impairment.
Estonian: Neerufunktsiooni kahjustusega patsientidel ei ole spetsiaalseid uuringuid läbi viidud.
English: - Ensure your hands are dry before picking up your tablet(s).
Estonian: - Enne tableti (tablettide) käsitsemist veenduge, et teie käed on kuivad.
English: NAME OF THE MEDICINAL PRODUCT Cladribine 10 mg
Estonian: RAVIMPREPARAADI NIMETUS Cladribine 10 mg
English: Rare (≥1/10,000 to <1/1,000)
Estonian: Harv (≥ 1/10 000 kuni < 1/1000)
English: Caution: Do not remove the tray from the carton.
Estonian: Ärge tõmmake alust karbist välja.
English: Skin and subcutaneous tissue disorders Common:
Estonian: neutrofiilide arvu vähenemine Naha ja nahaaluskoe kahjustused Sage:
English: The effect on lymphocyte count is dose-dependent.
Estonian: Toime lümfotsüütide arvule sõltub ravimi annusest.
English: Talk to your doctor before taking MAVENCLAD if you have liver problems.
Estonian: Pidage nõu oma arstiga, kui lähete MAVENCLAD-ravilt üle mõnele muule hulgiskleroosi ravile.
English: Fructose intolerance
Estonian: Pahaloomulised kasvajad
English: 3 Pull out tray until it stops
Estonian: 3 Tõmmake alus nii kaugele välja kui võimalik.
English: Talk to your doctor if you have previously had cancer.
Estonian: Kui teil on eelnevalt olnud vähk, pidage nõu oma arstiga.
English: Initiation of treatment with MAVENCLAD must be postponed for 4 to 6 weeks to allow for the full effect of vaccination to occur.
Estonian: Vaktsineerimise täieliku toime avaldumiseks tuleb MAVENCLAD-ravi alustamine 4…6 nädalat edasi lükata.
English: A Step-by-Step Guide to taking your MAVENCLAD 10 mg tablets
Estonian: Üksikasjalik juhend MAVENCLAD'i 10 mg tablettide võtmiseks
English: STATEMENT OF ACTIVE SUBSTANCE Each tablet contains 10 mg cladribine.
Estonian: TOIMEAINE(TE) SISALDUS Üks tablett sisaldab 10 mg kladribiini.
English: There is limited experience with overdose of oral cladribine.
Estonian: Kogemused kladribiini tablettide üleannustamisega on piiratud.
English: In a male mouse fertility study, malformed foetuses with agenesis of portions of appendage(s) distal the humerus and/or femur were seen.
Estonian: Isashiirte fertiilsusuuringus täheldati loodete väärarenguid, nt õlavarreluu ja/või reieluu distaalse(te) jätke(te) ageneesi.
English: Therefore, it is recommended that administration of any other oral medicinal product be separated from that of MAVENCLAD by at least 3 hours during the limited number of days of cladribine administration.
Estonian: Seetõttu soovitatakse kladribiini kasutamise päevadel jätta muude suukaudsete ravimite ja MAVENCLAD'i manustamise vahele vähemalt 3 tundi.
English: MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
Estonian: RAVIMIPARTII KASUTAMISEKS VABASTAMISE EEST VASTUTAVAD TOOTJAD
English: 1 Open flap
Estonian: 1 Avage karü.
English: Vaccination with live or attenuated live vaccines should be avoided during and after cladribine treatment as long as the patient's white blood cell counts are not within normal limits.
Estonian: Nii kaua kui patsiendi vere valgeliblede arv ei ole normivahemikus, tuleb kladribiinravi ajal ja pärast seda vältida vaktsineerimist elusvaktsiinidega või nõrgestatud elusvaktsiinidega.
English: Take the leaflet from the tray.
Estonian: Võtke infoleht karbist välja.
English: You must use effective methods of contraception to avoid becoming pregnant during MAVENCLAD treatment and for 6 months after taking the last dose.
Estonian: Rasestumise vältimiseks peate kasutama efektiivseid rasestumisvastaseid vahendeid MAVENCLAD-ravi ajal ja 6 kuud pärast MAVENCLAD'i viimase annuse võtmist.
English: Do not take MAVENCLAD, if you are breast-feeding.
Estonian: Ärge võtke imetamise ajal MAVENCLAD'i.
English: Lymphopenia
Estonian: Lümfopeenia
English: There is limited experience with overdose of MAVENCLAD.
Estonian: MAVENCLAD'i üleannustamise kohta on andmed piiratud.
English: Talk to your doctor or pharmacist before taking MAVENCLAD.
Estonian: Enne MAVENCLAD'i võtmist pidage nõu oma arsti või apteekriga.
English: Cladribine has the potential to penetrate the blood brain barrier.
Estonian: Kladribiin võib läbida hematoentsefaalbarjääri.
English: NAME OF THE MEDICINAL PRODUCT MAVENCLAD 10 mg tablets cladribine
Estonian: RAVIMPREPARAADI NIMETUS MAVENCLAD 10 mg tabletid kladribiin
English: You need a second method of contraception during MAVENCLAD treatment and for at least 4 weeks after the last dose.
Estonian: Te peate MAVENCLAD-ravi ajal ja vähemalt 4 nädalat pärast viimast annust kasutama lisaks mõnda teist rasestumisvastast meetodit.
English: Treatment courses
Estonian: Ravikuurid
English: Malignancies
Estonian: Mutageensus
English: Annualised relapse rate (95% CI) Relative reduction (cladribine vs. placebo) Proportion of patients relapse-free over 96 weeks Time to 3-month EDSS progression,
Estonian: Retsidiivide esinemissagedus aastas (95% usaldusvahemik) Suhteline vähenemine (kladribiin vs. platseebo)
English: Dose
Estonian: Ettevaatust!
English: Following oral administration, cladribine is rapidly absorbed.
Estonian: Kladribiin imendub kiiresti pärast suukaudset manustamist.
English: Posology
Estonian: Kaaluvahemik
English: Male patients must take precautions to prevent pregnancy of their female partner during cladribine treatment and for at least 6 months after the last dose.
Estonian: Meessoost patsiendid peavad kladribiinravi ajal ja vähemalt 6 kuud pärast viimase annuse võtmist kasutama ettevaatusabinõusid oma naissoost partneri rasestumise vältimiseks.
English: Post-hoc subgroup efficacy analyses have been conducted in patients with high disease activity treated with oral cladribine at the recommended 3.5 mg/kg cumulative dose.
Estonian: Soovitatavas kumulatiivses annuses 3,5 mg/kg suukaudset kladribiinravi saanud, eriti aktiivse haigusega patsientidel viidi läbi alamrühma post-hoc efektiivsusanalüüsid.
English: Therefore, male patients must take precautions to prevent pregnancy of their partner during cladribine treatment and for at least 6 months after the last dose.
Estonian: Seetõttu peavad meessoost patsiendid kladribiinravi ajal ja vähemalt 6 kuud pärast viimase annuse võtmist kasutama ettevaatusabinõusid oma partneri rasestumise vältimiseks.
English: • Important identified risks Severe (Grade ≥ 3) lymphopenia, to ensure compliance to haematological testing and treatment requirements; Herpes zoster infections, to ensure awareness of signs and symptoms suggestive for these infections; Tuberculosis, to raise awareness about this risk.
Estonian: Vöötohatise infektsioonid, teadlikkuse tagamiseks neile infektsioonidele viitavate nähtude ja sümptomite osas.
English: Women using systemically acting hormonal contraceptives should add a barrier method during cladribine treatment and for at least 4 weeks after the last dose in each treatment year (see section 4.5).
Estonian: Kladribiinravi ajal ja vähemalt 4 nädalat pärast viimast annust peavad süsteemse toimega hormonaalseid rasestumisvastaseid vahendeid kasutavad naised igal raviaastal kasutama lisaks mõnda barjäärimeetodit (vt lõik 4.5).
English: Blood and lymphatic system disorders Very common: Lymphopenia.
Estonian: tuberkuloos (vt lõik 4.4) Vere ja lümfisüsteemi häired Väga sage:
English: Contraception
Estonian: Rasestumisvastased vahendid
English: Liver problems
Estonian: Maksaga seotud probleemid
English: Relapsing-remitting MS
Estonian: Ägenemiste ja retsidiividega kulgev SM
English: Patients with lymphocyte counts below 500 cells/mm³ should be actively monitored for signs and symptoms suggestive of infections, in particular herpes zoster.
Estonian: Patsiente, kelle lümfotsüütide arv on alla 500 raku/mm
English: This summary was last updated in 04-2013.
Estonian: Kokkuvõtte viimane uuendus: 04-2013.
English: Nemdatine memantine
Estonian: Nemdatine memantiin
English: Nemdatine should be given once a day at the same time every day.
Estonian: Nemdatinet peab võtma üks kord ööpäevas, iga päev samal kellaajal.
English: What measures are being taken to ensure the safe and effective use of Nemdatine?
Estonian: Mis meetmed võetakse, et tagada Nemdatine kasutamise efektiivsus ja ohutus?
English: The full EPAR for Nemdatine can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Nemdatine kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What is Nemdatine and what is it used for?
Estonian: Mis on Nemdatine ja milleks seda kasutatakse?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Nemdatine on 22 April 2013.
Estonian: Euroopa Komisjon andis Nemdatine müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 22. aprillil
English: Other information about Nemdatine
Estonian: Muu teave Nemdatine kohta
English: The Committee recommended that Nemdatine be approved for use in the EU.
Estonian: Komitee soovitas Nemdatine kasutamise Euroopa Liidus heaks kiita.
English: Treatment should only be started if a caregiver is available who will regularly monitor the use of Nemdatine by the patient.
Estonian: Ravi tohib alustada vaid juhul, kui on olemas hooldaja, kes jälgib regulaarselt, kuidas patsient Nemdatinet kasutab.
English: The tolerance and dose should be assessed within 3 months after starting treatment, and from then on the benefits of continuing treatment with Nemdatine should be reassessed on a regular basis.
Estonian: Ravimi taluvust ja annust tuleb hinnata 3 kuu jooksul alates ravi algusest, seejärel tuleb Nemdatine-ravi jätkamist regulaarselt uuesti hinnata.
English: To prevent side effects, the dose of Nemdatine is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day.
Estonian: Kõrvalnähtude ennetamiseks suurendatakse Nemdatine annust esimese kolme ravinädala jooksul järk-järgult: esimesel nädalal on annus 5 mg, teisel nädalal 10 mg ning kolmandal nädalal 15 mg.
English: By blocking NMDA receptors, memantine improves the transmission of signals in the brain and reduces the symptoms of Alzheimer's disease.
Estonian: NMDA-retseptorite blokeerimisega parandab memantiin signaalide edastamist ajus ja vähendab Alzheimeri tõve sümptomeid.
English: Nemdatine is a ‘generic medicine'.
Estonian: Nemdatine on geneeriline ravim.
English: Nemdatine is available as 5 mg, 10 mg, 15 mg and 20 mg tablets and can only be obtained with a prescription.
Estonian: Nemdatine on retseptiravim ja seda turustatakse 5 mg, 10 mg, 15 mg ja 20 mg tablettidena.
English: Why is Nemdatine approved?
Estonian: Miks Nemdatine heaks kiideti?
English: It is not intended to provide practical advice on how to use Nemdatine.
Estonian: Hindamisaruandes ei anta Nemdatine kasutamise praktilisi nõuandeid.
English: Neurotransmitters are chemicals in the nervous system that allow nerve cells to communicate with one another.
Estonian: Neurotransmitterid on närvisüsteemi keemilised ained, mis vahendavad signaale närvirakkude vahel.
English: In addition, overstimulation of the NMDA receptors may result in cell damage or death.
Estonian: NMDA-retseptorite liigne stimuleerimine võib rakke kahjustada või hävitada.
English: The cause of Alzheimer's disease is unknown, but memory loss in the disease is believed to be due to a disturbance of message signals in the brain.
Estonian: Alzheimeri tõve tekkepõhjus ei ole teada, kuid mälukaotus selle haiguse korral arvatakse tulenevat aju närviimpulsside häiretest.
English: Nemdatine is a medicine used to treat patients with moderate to severe Alzheimer's disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.
Estonian: Alzheimeri tõbi on dementsuse (teatud ajuhäire) liik, mis kahjustab järk-järgult mälu, vaimseid võimeid ja käitumist.
English: The dose may need to be reduced in patients who have moderate or severe problems with their kidneys.
Estonian: Mõõdukate või raskete neeruprobleemidega patsientidel võib olla vaja annust vähendada.
English: Because Nemdatine is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Nemdatine on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Therefore, the CHMP's view was that, as for Ebixa, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Ebixa korral, ületab Nemdatine kasulikkus sellega kaasnevad riskid.
English: Memantine works by blocking special types of receptor called NMDA receptors to which the neurotransmitter glutamate normally attaches.
Estonian: Memantiini toime seisneb selles, et see blokeerib teatud retseptoreid (NMDA-retseptoreid), millele tavaliselt kinnitub neurotransmitter glutamaat.
English: This means that Nemdatine is similar to a ‘reference medicine' already authorised in the European Union (EU) called Ebixa.
Estonian: See tähendab, et Nemdatine on sarnane võrdlusravimiga Ebixa, millel juba on Euroopa Liidus müügiluba.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Nemdatine, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Nemdatine ohutusteave koos vastavate ettevaatusabinõudega tervishoiuspetsialistidele ja patsientidele.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Nemdatine has been shown to have comparable quality and to be bioequivalent to Ebixa.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Nemdatine võrdväärne kvaliteet ja bioekvivalentsus ravimiga Ebixa.
English: How is Nemdatine used?
Estonian: Kuidas Nemdatinet kasutatakse?
English: For practical information about using Nemdatine, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Nemdatine kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Nemdatine, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Nemdatinega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Because Nemdatine is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Ebixa.
Estonian: Et Nemdatine on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Nemdatine bioekvivalentsust võrdlusravimiga Ebixa.
English: It contains the active substance memantine.
Estonian: Ravim sisaldab toimeainena memantiini.
English: The active substance in Nemdatine, memantine, is an antidementia medicine.
Estonian: Nemdatine toimeaine memantiin on dementsuse ravim.
English: This is a summary of the European public assessment report (EPAR) for Nemdatine.
Estonian: See on ravimi Nemdatine Euroopa avaliku hindamisaruande kokkuvõte.
English: How does Nemdatine work?
Estonian: Kuidas Nemdatine toimib?
English: How has Nemdatine been studied?
Estonian: Kuidas Nemdatinet uuriti?
English: What are the benefits and risks of Nemdatine?
Estonian: Milles seisneb Nemdatine kasulikkus ja mis riskid ravimiga kaasnevad?
English: For more information, see the package leaflet.
Estonian: Üksikasjalik teave on pakendi infolehel.
English: Treatment should be started and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease.
Estonian: Ravi Nemdatinega tohib alustada üksnes Alzheimeri tõvega patsientide diagnoosimises ja ravis kogenud arst ning see peab toimuma tema järelevalve all.
English: Changes in the way glutamate transmits signals within the brain have been linked to the memory loss seen in Alzheimer's disease.
Estonian: Alzheimeri tõve korral täheldatud mälukaotust on seostatud muudatustega viisis, kuidas glutamaat edastab ajus signaale.
English: fractures and heart failure).
Estonian: luumurrud ja südamepuudulikkus).
English: The Prescriber Guide should highlight the following:
Estonian: Retsepti väljakirjutaja juhend peab sisaldama järgmist:
English: Prior to distribution of the prescriber guide in each Member State, the MAH must agree the content and format of the educational material, together with a communication plan, with the national competent authority.
Estonian: Enne retsepti kirjutaja juhendi levitamist igas liikmesriigis peab müügiloa hoidja kooskõlastama riikliku pädeva asutusega koolitusmaterjalide sisu ja vormi koos kommunikatsiooniplaaniga.
English: • Caution in use in the elderly in light of age related risks (in particular bladder cancer,
Estonian: • Hoiatus kasutamisel eakatel patsientidel pidades silmas vananemisega seotud riske (eriti põievähk,
English: • Patient selection criteria including that Pioglitazone should not be used as first line therapy and emphasising the need for regular review of treatment benefit.
Estonian: • Patsiendi valiku kriteeriumid sealhulgas see, et pioglitasooni ei tohi kasutada esimese rea ravina ja rõhutama ravi kasu regulaarse jälgimise vajadust.
English: ANNEX CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
Estonian: LISA TINGIMUSED JA PIIRANGUD RAVIMI OHUTUKS NING TÕHUSAKS KASUTAMISEKS LIIKMESRIIKIDES
English: • The physician educational pack should contain: The Summary of Product Characteristics, package leaflet, and a Prescriber Guide.
Estonian: • Arsti koolituspakett peab sisaldama: ravimite omaduste kokkuvõtet, pakendi infolehte ja retsepti väljakirjutaja juhendit.
English: Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the member states.
Estonian: Tingimused ja piirangud ravimi ohutuks ning tõhusaks kasutamiseks liikmesriikides.
English: • This educational pack is aimed at strengthening awareness of important identified risks of bladder cancer and heart failure and the overall recommendations intended to optimise the benefit-risk margin at the patient level.
Estonian: • Selle koolituspaketi eesmärk on suurendada teadlikkust olulise tuvastatud põievähi ja südamepuudulikkuse riski ja üldiste soovituste osas kavatsusega optimeerida kasu-riski määra patsiendi tasandil.
English: The MAH shall provide an educational pack targeting all physicians who are expected to prescribe/use Pioglitazone.
Estonian: Müügiloa hoidja peab tagama koolituspaketi, mis on suunatud kõigile arstidele, kes eeldatavasti hakkavad välja kirjutama/kasutama pioglitasooni.
English: • The risk of heart failure and relevant risk minimisation advice.
Estonian: • Südamepuudulikkuse riski ning asjakohased riski minimeerimise nõuanded.
English: • The risk of bladder cancer and relevant risk minimisation advice.
Estonian: • Põievähi riski ning asjakohased riski minimeerimise nõuanded.
English: Package size l t o r
Estonian: Pakendi suurus l t o r
English: Packaging
Estonian: Manustamistee
English: Strength Pharmaceutical Form Route of Administration
Estonian: Tugevus Ravimvorm
English: EU Number
Estonian: Müügiloa nr Euroopa Liidus Nimi
English: Avoid vigorous mixing.
Estonian: Vältida tugevat segamist.
English: Do not refrigerate.
Estonian: Mitte lasta külmuda.
English: • severe allergic reactions,
Estonian: • rasked allergilised reaktsioonid;
English: In this study, semen analysis was conducted after 8 weeks of continuous treatment.
Estonian: Selles uuringus tehti spermaanalüüs pärast 8-nädalast pidevat ravi.
English: Tell your doctor if you are taking, have recently taken or might take any other medicines.
Estonian: Teatage oma arstile kui te võtate või olete hiljuti võtnud või kavatsete võtta mis tahes muid ravimeid.
English: This medicine will be given to you by a healthcare professional.
Estonian: Seda ravimit manustab teile tervishoiutöötaja.
English: Sorbitol is a source of fructose.
Estonian: Sorbitool on fruktoosi allikas.
English: Mean clearance was approximately 43.2 L/kg.
Estonian: Keskmine kliirens oli ligikaudu 43,2 l/kg.
English: The doctor will decide if you will need to be treated for longer periods.
Estonian: Arst otsustab, kas vajate pikemaajalist ravi.
English: The bolus and infusion should be initiated prior to the procedure and continued for at least two hours or for the duration of the procedure, whichever is longer.
Estonian: Boolust ja infusiooni tuleb alustada enne protseduuri ja jätkata vähemalt kahe tunni jooksul või protseduuri vältel, kui see kestab kauem.
English: België/Belgique/Belgien
Estonian: Belgiė/Belgique/Belgien
English: • Bleeding from anywhere in the body.
Estonian: • Verejooks keha ükskõik millises kohas.
English: The recommended dose is:
Estonian: Soovitatav annus on:
English: GP IIb/IIIa inhibitors were permitted for bailout use only and were used in 2.9% of patients.
Estonian: Glükoproteiin IIb/IIIa inhibiitoreid lubati kasutada ainult päästva ravimina ja neid kasutati 2,9% patsientidest.
English: The median duration of cangrelor infusion was 129 minutes.
Estonian: Kangreloori infusiooni keskmine kestus oli 129 minutit.
English: Tell your doctor immediately if you notice any of the following:
Estonian: Öelge oma arstile kohe, kui te märkate mõnda järgmistest kõrvaltoimetest:
English: Initial excretion was rapid, such that approximately 50% of the administered radioactivity was recovered in the first 24 hours, and 75% was recovered by 48 hours.
Estonian: Algne eritumine toimus kiiresti, ligikaudu 50% manustatud radioaktiivsusest eritus esimese 24 tunni jooksul ja 75% väljus 48 tunni jooksul.
English: Other medicines and Kengrexal
Estonian: Muud ravimid ja Kengrexal
English: If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Estonian: Kui te olete rase või arvate end olevat rase või kavatsete rasestuda, pidage enne selle ravimi kasutamist nõu oma arstiga.
English: Adverse reactions are classified according to frequency and system organ class.
Estonian: Kõrvaltoimed on liigitatud esinemissageduse ja organsüsteemide järgi.
English: During this procedure you may have a stent inserted in your blood vessel to help to keep it open.
Estonian: Selle protseduuri käigus võidakse sisestada teie veresoonde stent, mis aitab seda avatuna hoida.
English: No dose adjustment is needed in elderly (≥75 years) patients.
Estonian: Annuse kohandamine eakatel patsientidel (≥ 75 aastat) ei ole vajalik.